Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Contraception with norethindrone 0.35 mg administered continuously.

J A Board

    Southern Medical Journal
    |January 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Grand challenges in biomedical computing.

    Critical reviews in biomedical engineering·1992
    Same author

    Spironolactone and estrogen-progestin therapy for hirsutism.

    Southern medical journal·1987
    Same author

    High-molecular weight dextran in human infertility surgery.

    American journal of obstetrics and gynecology·1984
    Same author

    Nocturnal prolactin levels in infertility.

    Fertility and sterility·1981
    Same author

    Effect of cyproheptadine on chlorpromazine stimulation of prolactin in women.

    American journal of obstetrics and gynecology·1981
    Same author

    Factitious trophoblastic disease: Münchausen's mole.

    Southern medical journal·1980

    Microdose norethindrone (0.35 mg daily) demonstrated high contraceptive effectiveness, with a drug-effectiveness rate of 1.9 per 100 woman-years. This oral contraceptive showed variable cycle length and a tendency toward weight gain but no significant blood pressure changes.

    Area of Science:

    • Reproductive Health
    • Endocrinology
    • Pharmacology

    Background:

    • Oral contraceptives are widely used for family planning.
    • Norethindrone is a progestin hormone used in hormonal contraception.
    • Microdose formulations offer potential advantages in efficacy and side effect profiles.

    Purpose of the Study:

    • To evaluate the effectiveness and safety of microdose norethindrone (0.35 mg daily) as an oral contraceptive.
    • To assess pregnancy rates and associated factors with continuous use of this microdose formulation.
    • To monitor for potential side effects, including changes in cycle length, weight, and blood pressure.

    Main Methods:

    • A prospective study involving 168 women using 0.35 mg norethindrone daily for 4,264 months over five years.

    Related Experiment Videos

  • Pregnancy rates were calculated using drug-effectiveness and use-effectiveness metrics (per 100 woman-years).
  • Cycle length, weight, blood pressure, and metyrapone test results were monitored.

    • Main Results:

    • A drug-effectiveness rate of 1.9 and a use-effectiveness rate of 2.5 pregnancies per 100 woman-years were observed.
    • Variable menstrual cycle length was noted.
    • A tendency toward weight gain was observed, but no definitive blood pressure trends emerged without control groups.
    • Metyrapone tests remained normal after 17-33 months of treatment.

    Conclusions:

    • Microdose norethindrone (0.35 mg daily) is a highly effective oral contraceptive agent.
    • The formulation is generally well-tolerated, with normal endocrine function indicated by metyrapone tests.
    • Further research with control groups is recommended to confirm observations on weight and blood pressure.